jade Biosciences Announces Interim Results From Its Phase 1 Trial Evaluating JADE101, A Novel, Investigational AntI-A Proliferation-Inducing Ligand Monoclonal Antibody In Development For The Treatment Of Immunoglobulin A Nephropathyl; JADE101 Showed Favorable Safety Profile And Well-Tolerated Across All Evaluated Subcutaneous Dose Levels